Home

venBio Global Strategic Fund II L.P.

CIK 1634632 · last filed 2022-05-04

venBio Global Strategic Fund II L.P. is a corporate insider who has filed 4 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing shows the insider sold $14.0M of CMPI on May 4, 2022. Across all open-market trades the lifetime net is −$36.3M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

4

Lifetime Open-Market Net

-$36.26M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Checkmate Pharmaceuticals, Inc. (CMPI) Delisted 10%+ Owner 2,535,158 $10.50 $26.62M -$42.55M 2 2022-05-04
VYNE Therapeutics Inc. (MNLO) Delisted 10%+ Owner 1,461,552 — — $4.50M 1 2018-01-29
Apellis Pharmaceuticals, Inc. (APLS) Delisted 10%+ Owner 3,451,790 $41.03 $141.63M $1.79M 1 2017-11-13

Recent Filings

4 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-05-04 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Sell (S) −1,353,375 -$14.05M EDGAR
2022-04-21 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Sell (S) −2,738,670 -$28.50M EDGAR
2018-01-29 VYNE Therapeutics Inc. (MNLO) Delisted Mixed +1,461,552 $4.50M EDGAR
2017-11-13 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed +3,579,305 $1.79M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.